Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus

Journal of Infection and Chemotherapy

Volumn 17, Issue 1, 2011, Pages 30-33

  Fujimura, Shigeru ^a   Fuse, Katsuhiro ^a,b   Takane, Hidenari ^a   Nakano, Yoshihisa ^a   Gomi, Kazunori ^b   Kikuchi, Toshiaki ^b   Watanabe, Akira ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AUC; Generic drug; PK PD; Teicoplanin

Indexed keywords

GENERIC DRUG; TEICOPLANIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 79951549877     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0094-0     Document Type: Article

References (10)

1. E Mastoraki A Michalopoulos I Kriaras E Mouchtouri ME Falagas D Karatza, et al. 2008 Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime J Infect 56 35 39 10.1016/j.jinf.2008.02.004 17983660 (Pubitemid 350253651)
2. CA Rodriguez M Agudelo JC Catano AF Zuluaga O Vesga 2009 Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia J Infect 59 277 280 10.1016/j.jinf.2009.08.005 19698745
3. S Fujimura K Fuse T Kikuchi K Gomi Y Tokue A Watanabe 2008 In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin Int J Antimicrob Agents 31 391 392 1:CAS:528:DC%2BD1cXjs1Kgt7k%3D 10.1016/j.ijantimicag.2008.01.002 18308516 (Pubitemid 351400375)
4. Clinical and Laboratory Standards Institute (2009) Perfomance standards for antimicrobial susceptibility testing, 19th edn. Approved standard M100-S19. CLSI, Wayne, PA.
5. Ministry of Health, Labour and Welfare (2006) Teicoplanin. The Japanese pharmacopoeia, 15th edn. Ministry of Health, Labour and Welfare, Tokyo, Japan, pp 733-735.
6. K Nakayama H Gemma A Kaibara T Niwa 2006 Population pharmacokinetics of teicoplanin in adult patients Jpn J Chemother 54 1 6 1:CAS:528: DC%2BD28Xhtlelsrw%3D (Pubitemid 43246295)
7. JL Kuti CRV Kiffer CMF Mendes DP Nicolau 2008 Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil Clin Microbiol Infect 14 116 123 1:CAS:528: DC%2BD1cXis1agtrg%3D 10.1111/j.1469-0691.2007.01885.x 18076672
8. GC Schito MH Keenan 2005 Predicting the clinical efficacy of generic formulations of ceftriaxone J Chemother 17 suppl 2 33 40 1:CAS:528: DC%2BD2MXhtlaisLrN 16315582 (Pubitemid 41686774)
9. M Martin S Quilici T File J Garau A Kureishi M Kubin 2007 Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance J Antimicrob Chemother 59 977 989 1:CAS:528:DC%2BD2sXmt1elsrk%3D 10.1093/jac/dkm033 17395688 (Pubitemid 47073371)
10. Japan Antibiotics Research Association (2000) Teicoplanin for injection. Requirements for antibiotic products of Japan. Jiho Co., Tokyo, Japan, p II-39.